Support for 5-HT2C receptor functional selectivity in vivo utilizing structurally diverse, selective 5-HT2C receptor ligands and the 2,5-dimethoxy-4-iodoamphetamine elicited head-twitch response model

Neuropharmacology

Volumn 70, Issue , 2013, Pages 112-121

  Canal, Clinton E ^a,b   Booth, Raymond G ^a,b   Morgan, Drake ^c  

^a UNIVERSITY OF FLORIDA   (United States)

^b NORTHEASTERN UNIVERSITY   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

C57Bl 6J; DOI; Functional selectivity; Hallucinogen; Head twitch response; Mouse serotonin 2A receptor; Mouse serotonin 2C receptor

Indexed keywords

1 METHYLPSILOCIN; 1,2,3,5 TETRAHYDRO 5 METHYL 1 (3 PYRIDYLCARBAMOYL)PYRROLO[2,3 F]INDOLE; 2 (6 CHLORO 5 FLUORO 1 INDOLYL) 1 METHYLETHYLAMINE; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; 6 CHLORO 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL]INDOLINE; 8,9 DICHLORO 2,3,4,4A TETRAHYDRO 1H PYRAZINO[1,2 A]QUINOXALIN 5(6H) ONE; CP 809101; LIGAND; PHOSPHOLIPASE C; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN 2C AGONIST; SEROTONIN 2C ANTAGONIST; SEROTONIN 2C RECEPTOR; UNCLASSIFIED DRUG; VOLINANSERIN;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SELECTIVITY; HEAD TWITCH; HYDROLYSIS; IN VITRO STUDY; IN VIVO STUDY; LOCOMOTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

AMPHETAMINES; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DYSKINESIA, DRUG-INDUCED; HEK293 CELLS; HUMANS; LOCOMOTION; MALE; MICE; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTOR, SEROTONIN, 5-HT2C; SEROTONIN 5-HT2 RECEPTOR AGONISTS; SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS; TICS; TYPE C PHOSPHOLIPASES;

EID: 84876976859     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2013.01.007     Document Type: Article

References (64)

1. A. Abbas, and B.L. Roth Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders Expert Opin. Pharmacother. 9 2008 3251 3259
2. A.I. Abbas, P.N. Yadav, W.D. Yao, M.I. Arbuckle, S.G. Grant, M.G. Caron, and B.L. Roth PSD-95 is essential for hallucinogen and atypical antipsychotic drug actions at serotonin receptors J. Neurosci. 29 2009 7124 7136
3. Arena Pharmaceuticals Inc. Arena Pharmaceuticals and Eisai Announce FDA Approval of BELVIQ® (Lorcaserin HCl) for Chronic Weight Management in Adults Who are Overweight with a Comorbidity or Obese 2012 http://invest.arenapharm. com/releasedetail.cfm?ReleaseID=687182
4. C. Becamel, S. Gavarini, B. Chanrion, G. Alonso, N. Galeotti, A. Dumuis, J. Bockaert, and P. Marin The serotonin 5-HT2A and 5-HT2C receptors interact with specific sets of PDZ proteins J. Biol. Chem. 279 2004 20257 20266
5. J.M. Bentley, D.R. Adams, D. Bebbington, K.R. Benwell, M.J. Bickerdike, J.E. Davidson, C.E. Dawson, C.T. Dourish, M.A. Duncton, S. Gaur, A.R. George, P.R. Giles, R.J. Hamlyn, G.A. Kennett, A.R. Knight, C.S. Malcolm, H.L. Mansell, A. Misra, N.J. Monck, R.M. Pratt, K. Quirk, J.R. Roffey, S.P. Vickers, and I.A. Cliffe Indoline derivatives as 5-HT(2C) receptor agonists Bioorg. Med. Chem. Lett. 14 2004 2367 2370
6. R.G. Booth, L. Fang, Y. Huang, A. Wilczynski, and S. Sivendran (1R, 3S)-(-)-trans-PAT: a novel full-efficacy serotonin 5-HT2C receptor agonist with 5-HT2A and 5-HT2B receptor inverse agonist/antagonist activity Eur. J. Pharmacol. 615 2009 1 9
7. E.C. Bucholtz, R.L. Brown, A. Tropsha, R.G. Booth, and S.D. Wyrick Synthesis, evaluation, and comparative molecular field analysis of 1-phenyl-3-amino-1,2,3,4-tetrahydronaphthalenes as ligands for histamine H(1) receptors J. Med. Chem. 42 1999 3041 3054
8. C.M. Burns, H. Chu, S.M. Rueter, L.K. Hutchinson, H. Canton, E. Sanders-Bush, and R.B. Emeson Regulation of serotonin-2C receptor G-protein coupling by RNA editing Nature 387 1997 303 308
9. K.D. Burris, M. Breeding, and E. Sanders-Bush (+)Lysergic acid diethylamide, but not its nonhallucinogenic congeners, is a potent serotonin 5HT1C receptor agonist J. Pharmacol. Exp. Ther. 258 1991 891 896
10. C.E. Canal, T.C. Cordova-Sintjago, N.Y. Villa, L.J. Fang, and R.G. Booth Drug discovery targeting human 5-HT(2C) receptors: residues S3.36 and Y7.43 impact ligand-binding pocket structure via hydrogen bond formation Eur. J. Pharmacol. 673 2011 1 12
11. C.E. Canal, and D. Morgan Head-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model Drug Test. Anal. 4 2012 556 576
12. C.E. Canal, U.B. Olaghere da Silva, P.J. Gresch, E.E. Watt, E. Sanders-Bush, and D.C. Airey The serotonin 2C receptor potently modulates the head-twitch response in mice induced by a phenethylamine hallucinogen Psychopharmacology (Berl) 209 2010 163 174
13. Y. Cheng, and W.H. Prusoff Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction Biochem. Pharmacol. 22 1973 3099 3108
14. S.J. Corne, and R.W. Pickering A possible correlation between drug-induced hallucinations in man and a behavioural response in mice Psychopharmacologia 11 1967 65 78
15. K.A. Cunningham, R.G. Fox, N.C. Anastasio, M.J. Bubar, S.J. Stutz, F.G. Moeller, S.R. Gilbertson, and S. Rosenzweig-Lipson Selective serotonin 5-HT(2C) receptor activation suppresses the reinforcing efficacy of cocaine and sucrose but differentially affects the incentive-salience value of cocaine- vs. sucrose-associated cues Neuropharmacology 61 2011 513 523
16. D. Cussac, E. Boutet-Robinet, M.C. Ailhaud, A. Newman-Tancredi, J.C. Martel, N. Danty, and I. Rauly-Lestienne Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells Eur. J. Pharmacol. 594 2008 32 38
17. D. Cussac, A. Newman-Tancredi, Y. Quentric, N. Carpentier, G. Poissonnet, J.G. Parmentier, S. Goldstein, and M.J. Millan Characterization of phospholipase C activity at h5-HT2C compared with h5-HT2B receptors: influence of novel ligands upon membrane-bound levels of [3H]phosphatidylinositols Naunyn Schmiedebergs Arch. Pharmacol. 365 2002 242 252
18. K.J. Damjanoska, N.A. Muma, Y. Zhang, D.N. D'Souza, F. Garcia, G.A. Carrasco, G.H. Kindel, K.A. Haskins, M. Shankaran, B.R. Petersen, and L.D. Van De Kar Neuroendocrine evidence that (S)-2-(chloro-5-fluoro-indol- l-yl)-1-methylethylamine fumarate (Ro 60-0175) is not a selective 5-hydroxytryptamine(2C) receptor agonist J. Pharmacol. Exp. Ther. 304 2003 1209 1216
19. N.A. Darmani, B.R. Martin, U. Pandey, and R.A. Glennon Do functional relationships exist between 5-HT1A and 5-HT2 receptors? Pharmacol. Biochem. Behav. 36 1990 901 906
20. J.P. Dougherty, and V.J. Aloyo Pharmacological and behavioral characterization of the 5-HT2A receptor in C57BL/6N mice Psychopharmacology (Berl) 215 2011 581 593
21. J. Dunlop, T. Lock, B. Jow, F. Sitzia, S. Grauer, F. Jow, A. Kramer, M.R. Bowlby, A. Randall, D. Kowal, A. Gilbert, T.A. Comery, J. Larocque, V. Soloveva, J. Brown, and R. Roncarati Old and new pharmacology: positive allosteric modulation of the alpha7 nicotinic acetylcholine receptor by the 5-hydroxytryptamine(2B/C) receptor antagonist SB-206553 (3,5-dihydro-5-methyl-N- 3-pyridinylbenzo[1,2-b:4,5-b']di pyrrole-1(2H)-carboxamide) J. Pharmacol. Exp. Ther. 328 2009 766 776
22. B.H. Ebdrup, H. Rasmussen, J. Arnt, and B. Glenthoj Serotonin 2A receptor antagonists for treatment of schizophrenia Expert Opin. Investig. Drugs 20 2011 1211 1223
23. W.E. Fantegrossi, J. Simoneau, M.S. Cohen, S.M. Zimmerman, C.M. Henson, K.C. Rice, and J.H. Woods Interaction of 5-HT2A and 5-HT2C receptors in R(-)-2,5-dimethoxy-4-iodoamphetamine-elicited head twitch behavior in mice J. Pharmacol. Exp. Ther. 335 2010 728 734
24. P.J. Fletcher, M. Tampakeras, J. Sinyard, A. Slassi, M. Isaac, and G.A. Higgins Characterizing the effects of 5-HT(2C) receptor ligands on motor activity and feeding behaviour in 5-HT(2C) receptor knockout mice Neuropharmacology 57 2009 259 267
25. C.S. Flordellis The plasticity of the 7TMR signaling machinery and the search for pharmacological selectivity Curr. Pharm. Des. 18 2012 145 160
26. J.C. Fowler, S. Bhattacharya, J.D. Urban, N. Vaidehi, and R.B. Mailman Receptor conformations involved in dopamine D2L receptor functional selectivity induced by selected transmembrane 5 serine mutations Mol. Pharmacol. 81 2012 820 831
27. M. Fox, H. French, J. LaPorte, A. Blackler, and D. Murphy The serotonin 5-HT2A receptor agonist TCB-2: a behavioral and neurophysiological analysis Psychopharmacology 212 2010 13 23
28. E.E. Garcia, R.L. Smith, and E. Sanders-Bush Role of G(q) protein in behavioral effects of the hallucinogenic drug 1-(2,5-dimethoxy-4-iodophenyl)-2- aminopropane Neuropharmacology 52 2007 1671 1677
29. S.D. Gleason, V.L. Lucaites, H.E. Shannon, D.L. Nelson, and J.D. Leander m-CPP hypolocomotion is selectively antagonized by compounds with high affinity for 5-HT(2C) receptors but not 5-HT(2A) or 5-HT(2B) receptors Behav. Pharmacol. 12 2001 613 620
30. J. Gonzalez-Maeso, R.L. Ang, T. Yuen, P. Chan, N.V. Weisstaub, J.F. Lopez-Gimenez, M. Zhou, Y. Okawa, L.F. Callado, G. Milligan, J.A. Gingrich, M. Filizola, J.J. Meana, and S.C. Sealfon Identification of a serotonin/glutamate receptor complex implicated in psychosis Nature 452 2008 93 97
31. J. Gonzalez-Maeso, N.V. Weisstaub, M. Zhou, P. Chan, L. Ivic, R. Ang, A. Lira, M. Bradley-Moore, Y. Ge, Q. Zhou, S.C. Sealfon, and J.A. Gingrich Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior Neuron 53 2007 439 452
32. J. Gonzalez-Maeso, T. Yuen, B.J. Ebersole, E. Wurmbach, A. Lira, M. Zhou, N. Weisstaub, R. Hen, J.A. Gingrich, and S.C. Sealfon Transcriptome fingerprints distinguish hallucinogenic and nonhallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in mouse somatosensory cortex J. Neurosci. 23 2003 8836 8843
33. A.L. Halberstadt, L. Koedood, S.B. Powell, and M.A. Geyer Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice J. Psychopharmacol. 25 2011 1548 1561
34. A.L. Halberstadt, I. van der Heijden, M.A. Ruderman, V.B. Risbrough, J.A. Gingrich, M.A. Geyer, and S.B. Powell 5-HT(2A) and 5-HT(2C) receptors exert opposing effects on locomotor activity in mice Neuropsychopharmacology 34 2009 1958 1967
35. L.K. Heisler, and L.H. Tecott A paradoxical locomotor response in serotonin 5-HT(2C) receptor mutant mice J. Neurosci. 20 2000 RC71
36. K. Herrick-Davis, E. Grinde, T. Lindsley, A. Cowan, and J.E. Mazurkiewicz Oligomer size of the serotonin 5-hydroxytryptamine 2C (5-HT2C) receptor revealed by fluorescence correlation spectroscopy with photon counting histogram analysis: evidence for homodimers without monomers or tetramers J. Biol. Chem. 287 2012 23604 23614
37. K. Herrick-Davis, E. Grinde, and J.E. Mazurkiewicz Biochemical and biophysical characterization of serotonin 5-HT2C receptor homodimers on the plasma membrane of living cells Biochemistry 43 2004 13963 13971
38. J.D. Hutcheson, V. Setola, B.L. Roth, and W.D. Merryman Serotonin receptors and heart valve disease-it was meant 2B Pharmacol. Ther. 132 2011 146 157
39. N.H. Jensen, T.I. Cremers, and F. Sotty Therapeutic potential of 5-HT2C receptor ligands ScientificWorldJournal 10 2010 1870 1885
40. A.I. Kaya, H.O. Onaran, G. Ozcan, C. Ambrosio, T. Costa, S. Balli, and O. Ugur Cell contact-dependent functional selectivity of beta2-adrenergic receptor ligands in stimulating cAMP accumulation and extracellular signal-regulated kinase phosphorylation J. Biol. Chem. 287 2012 6362 6374
41. A.R. Knight, A. Misra, K. Quirk, K. Benwell, D. Revell, G. Kennett, and M. Bickerdike Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors Naunyn Schmiedebergs Arch. Pharmacol. 370 2004 114 123
42. B. Koener, M.C. Focant, B. Bosier, J.M. Maloteaux, and E. Hermans Increasing the density of the D2L receptor and manipulating the receptor environment are required to evidence the partial agonist properties of aripiprazole Prog. Neuropsychopharmacol. Biol. Psychiatry 36 2012 60 70
43. H.P. Landolt, and R. Wehrle Antagonism of serotonergic 5-HT2A/2C receptors: mutual improvement of sleep, cognition and mood? Eur. J. Neurosci. 29 2009 1795 1809
44. R.B. Mailman GPCR functional selectivity has therapeutic impact Trends Pharmacol. Sci. 28 2007 390 396
45. S. Mary, M. Damian, M. Louet, N. Floquet, J.A. Fehrentz, J. Marie, J. Martinez, and J.L. Baneres Ligands and signaling proteins govern the conformational landscape explored by a G protein-coupled receptor Proc. Natl. Acad. Sci. U. S. A. 109 2012 8304 8309
46. M.J. Millan Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies Therapie 60 2005 441 460
47. G. Milligan Mechanisms of multifunctional signalling by G protein-linked receptors Trends Pharmacol. Sci. 14 1993 239 244
48. J.M. Monti Serotonin 5-HT(2A) receptor antagonists in the treatment of insomnia: present status and future prospects Drugs Today (Barc) 46 2010 183 193
49. H.J. Motulsky, and A. Christopoulos Fitting Models to Biological Data Using Linear and Non-linear Regression. A Practical Guide to Curve-fitting 2003 GraphPad Software, Inc. San Diego, CA
50. P.R. Moya, K.A. Berg, M.A. Gutierrez-Hernandez, P. Saez-Briones, M. Reyes-Parada, B.K. Cassels, and W.P. Clarke Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-hydroxytryptamine (5-HT)2A and 5-HT2C receptors J. Pharmacol. Exp. Ther. 321 2007 1054 1061
51. D.E. Nichols Hallucinogens Pharmacol. Ther. 101 2004 131 181
52. R.H. Porter, K.R. Benwell, H. Lamb, C.S. Malcolm, N.H. Allen, D.F. Revell, D.R. Adams, and M.J. Sheardown Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells Br. J. Pharmacol. 128 1999 13 20
53. T.S. Ray Psychedelics and the human receptorome PLoS One 5 2010 e9019
54. S. Rosenzweig-Lipson, J. Zhang, H. Mazandarani, B.L. Harrison, A. Sabb, J. Sabalski, G. Stack, G. Welmaker, J.E. Barrett, and J. Dunlop Antiobesity-like effects of the 5-HT2C receptor agonist WAY-161503 Brain Res. 1073-1074 2006 240 251
55. S. Rosenzweig-Lipson, J. Dunlop, and K.L. Marquis 5-HT2C receptor agonists as an innovative approach for psychiatric disorders Drug News Perspect. 20 2007 565 571
56. H. Sard, G. Kumaran, C. Morency, B.L. Roth, B.A. Toth, P. He, and L. Shuster SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist Bioorg. Med. Chem. Lett. 15 2005 4555 4559
57. C.L. Schmid, and L.M. Bohn Serotonin, but not N-methyltryptamines, activates the serotonin 2A receptor via a ss-arrestin2/Src/Akt signaling complex in vivo J. Neurosci. 30 2010 13513 13524
58. C.L. Schmid, K.M. Raehal, and L.M. Bohn Agonist-directed signaling of the serotonin 2A receptor depends on beta-arrestin-2 interactions in vivo Proc. Natl. Acad. Sci. U. S. A. 105 2008 1079 1084
59. J.A. Siuciak, D.S. Chapin, S.A. McCarthy, V. Guanowsky, J. Brown, P. Chiang, R. Marala, T. Patterson, P.A. Seymour, A. Swick, and P.A. Iredale CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity Neuropharmacology 52 2007 279 290
60. B.R. Teegarden, H. Al Shamma, and Y. Xiong 5-HT(2A) inverse-agonists for the treatment of insomnia Curr. Top. Med. Chem. 8 2008 969 976
61. W.J. Thomsen, A.J. Grottick, F. Menzaghi, H. Reyes-Saldana, S. Espitia, D. Yuskin, K. Whelan, M. Martin, M. Morgan, W. Chen, H. Al-Shamma, B. Smith, D. Chalmers, and D. Behan Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization J. Pharmacol. Exp. Ther. 325 2008 577 587
62. J.D. Urban, W.P. Clarke, M. von Zastrow, D.E. Nichols, B. Kobilka, H. Weinstein, J.A. Javitch, B.L. Roth, A. Christopoulos, P.M. Sexton, K.J. Miller, M. Spedding, and R.B. Mailman Functional selectivity and classical concepts of quantitative pharmacology J. Pharmacol. Exp. Ther. 320 2007 1 13
63. A.S. Vincek, and R.G. Booth New Approach to 4-Phenyl-beta-aminotetralin from 4-(3-Halophenyl)tetralen-2-ol Phenylacetate Tetrahedron Lett. 50 2009 5107 5109
64. G.S. Welmaker, J.A. Nelson, J.E. Sabalski, A.L. Sabb, J.R. Potoski, D. Graziano, M. Kagan, J. Coupet, J. Dunlop, H. Mazandarani, S. Rosenzweig-Lipson, S. Sukoff, and Y. Zhang Synthesis and 5-hydroxytryptamine (5-HT) activity of 2,3,4,4a-tetrahydro-1H-pyrazino[1,2-a]quinoxalin-5-(6H)ones and 2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinoxalines Bioorg. Med. Chem. Lett. 10 2000 1991 1994